Takeaway
- In patients with HER2-low unresectable and/or metastatic breast cancer (mBC), the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy (49% reduction in risk of progression, and 36% reduction in risk of death).
- No new safety concerns were identified.
- HER2-low mBC...